1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Chronic Lymphocytic Leukemia: Opportunity Analysis and Forecasts to 2027

Chronic Lymphocytic Leukemia: Opportunity Analysis and Forecasts to 2027

  • November 2018
  • 151 pages
  • ID: 5748392
  • Format: PDF
  • By GlobalData

Summary

Table of Contents

Search Inside

Chronic Lymphocytic Leukemia: Opportunity Analysis and Forecasts to 2027

Summary
Chronic lymphocytic leukemia (CLL) is a form of cancer that originates from lymphocytes in the bone marrow and later invades the blood and/or lymphoid tissues.CLL treatment has been transformed since the novel oral targeted agents Imbruvica (ibrutinib), Zydelig (idelalisib), and Venclexta (venetoclax) were introduced to the market from 2014 onwards and challenged the prior dominance of chemoimmunotherapy regimens.

During the forecast period, the global CLL market will welcome five new drugs-Calquence (acalabrutinib), zanubrutinib, umbralisib, ublituximab, and Revlimid (lenalidomide).

It is estimated that the value of the CLL market in the 7MM (US, France, Germany, Italy, Spain, UK, and Canada) in 2017 was $7.7B. Among these sales, 79.5% ($6.1B) were generated in the US, with the 5EU representing the next largest region by sales, with an estimated 18.5% ($1.4B). Canada contributed the smallest proportion of sales, at 2.0% ($157M) of the global CLL market. By 2027, the US is forecast to represent a similar proportion of the 7MM sales, at 79.6%. The 5EU and Canada will account for 18.3% and 2.0% of the 7MM CLL market, respectively.

It is projected that the CLL sales will rise to $9.2B in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Canada) by 2027, at a modest compound annual growth rate (CAGR) of 1.8%. In particular, US CLL market is expected to grow more rapidly than the 5EU or Canada, increasing to $7.4B by 2027, at a still-modest CAGR of 1.9%. Sales in the other regions are also expected to increase by the end of the forecast period, with the 5EU and Canada having a CAGR of 1.7% and 1.8%, respectively.

This is driven by increasing incidence, driven primarily by aging populations, label expansions into the first-line setting for AbbVie/Roche’s Venclexta, frontline approval of the combination of AbbVie/Johnson & Johnson’s Imbruvica + Venclexta, and the increasing use of combination therapies instead of monotherapies or chemoimmunotherapy regimens.Generic and biosimilar erosion of some of the mainstays of CLL treatment is also expected during the forecast period, particularly the use of generic ibrutinib and biosimilar rituximab will lead to a decline in sales.

A lack of innovative drugs in the late-stage pipeline with novel mechanisms of action means that next-generation agents are not expected to generate significant sales.

The report "Chronic Lymphocytic Leukemia: Opportunity Analysis and Forecasts to 2027", answers the following key questions -
- Which pipeline agents are the most promising and expected to launch in the 7MM? What are the forecasted sales of these agents and what will be their impact in the CLL market?
- What are the main unmet needs in CLL, which pipeline drugs will fulfil these needs, and to what extent?
- What are the current research and development (R&D) strategies being explored and how can developers incorporate these methods into their business strategy?
- Key Opinions Leaders (KOLs) insights across the 7MM, relating to the current treatment options and opinions on the late and early stage pipeline agents

Companies mentioned: AbbVie, Acerta Pharma, ADC Therapeutics, Adlai Nortye Biopharma, Aptevo Therapeutics, ArQule, Asana BioSciences, Astellas, AstraZeneca, Bayer, BeiGene, Biogen Idec, BioInvent International, Boehringer Ingelheim, Boston Biomedical, Bristol-Myers Squibb, Celgene, Cellectar Biosciences, Celltrion, Celularity, Centaurus Biopharma, Cyclacel Pharmaceuticals, Dynavax Technologies, Eli Lilly, Esanex, Eureka Therapeutics, Genentech, Genmab, Genzyme, Gilead Sciences, GSK, Hoffmann-La Roche, Hybrigenics, Immunomedics, Incuron, Incyte, Innate Pharma, Innovative Cellular Therapeutics, Invectys, Johnson & Johnson, Juno Therapeutics, Karyopharm Therapeutics, Kiromic, Kite Pharma, LAM Therapeutics, Lundbeck, Mei Pharma, Merck & Co., Esanex, Eureka Therapeutics, Genentech, Genmab, Genzyme, Gilead Sciences, GSK, Hoffmann-La Roche, Hybrigenics, Immunomedics, Incuron, Incyte, Innate Pharma, Innovative Cellular Therapeutics, Invectys, Johnson & Johnson, Juno Therapeutics, Karyopharm Therapeutics, Kiromic, Kite Pharma, LAM Therapeutics, Lundbeck, Mei Pharma, Merck & Co., Millennium Pharmaceuticals, MingSight Pharmaceuticals, Miragen Therapeutics, Molecular Templates, MorphoSys, MundiPharma, Neon Therapeutics, Novartis, Oncternal Therapeutics, Pharmacyclics, Piqur Therapeutics, Portola Pharmaceuticals, Sanofi, Sunesis Pharmaceuticals, Surface Oncology, Teva, TG Therapeutics, Tolero Pharmaceuticals, Trillium Therapeutics, Verastem, Xencor, Zhejiang DTRM Biopharma, Ziopharm Oncology

Scope
- Overview of CLL, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized CLL therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in seven geographic regions, forecast from 2017 to 2027.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the CLL therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for CLL. The most promising candidates in late-stage development are profiled.
- Analysis of the current and future market competition in the global CLL market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global CLL market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CLL market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
30% Off

($10995)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Pipeline Review, H1 2019

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Pipeline Review, H1 2019

  • $ 3500
  • April 2019

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Pipeline Review, H1 2019SummaryAccording to the recently published report ’T Cell Surface Glycoprotein ...

Sepsis - Pipeline Review, H1 2019

Sepsis - Pipeline Review, H1 2019

  • $ 2000
  • April 2019

Sepsis - Pipeline Review, H1 2019SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Sepsis - Pipeline Review, H1 2019, provides an overview of the Sepsis (Infectious ...

Colitis Global Clinical Trials Review, H1, 2019

Colitis Global Clinical Trials Review, H1, 2019

  • $ 2500
  • April 2019

Colitis Global Clinical Trials Review, H1, 2019SummaryGlobalData’s clinical trial report, “Colitis Global Clinical Trials Review, H1, 2019" provides an overview of Colitis clinical trials scenario.This ...


ref:plp2018

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on